BALLERUP, Denmark, March 19, 2013 /CNW/ - LEO Pharma announces a
co-creation agreement with the National Psoriasis Foundation (NPF) in
the United States that puts patients at the heart of LEO Pharma's
innovation process. The move supports the dermatology company's aim to
develop future care solutions that address patients' real-life needs.
The co-creation agreement with the US National Psoriasis Foundation aims
to ensure that the needs of people suffering from psoriasis play a
central role in the development of LEO Pharma's future psoriasis care
solutions. Ultimately, LEO Pharma hopes that its agreement with NPF
will pave the way for improved care solutions that empower people to
better manage their psoriasis.
(Logo: http://photos.prnewswire.com/prnh/20130221/595427 )
"Patients have unique insights into their condition. That is why we are
involving patients as active participants in our innovation process. In
order to make a difference to the everyday lives of people with skin
conditions, we want to gain an understanding of their challenges - and
work together to find solutions," says Kim Kjoeller, Senior Vice
President Global Development, LEO Pharma.
The co-creation agreement is the latest step in LEO Pharma's approach to
patient care innovation. This approach - where the pharmaceutical
industry joins forces with external partners, such as patient
organisations - is gaining increasing recognition internationally.
"Healthcare research is at a crossroads. Developing new drugs for the
many conditions that still lack a cure or effective treatment is a
costly, complex and high-risk process, leading some pharmaceutical
companies to give up on entire disease areas. LEO Pharma wants to
involve patients in shaping future care solutions," adds Kim Kjoeller.
Co-creation with plaque psoriasis patients
LEO Pharma's co-creation with NPF, which begins on 23 March, is based on
the creation of Psoriasis Frontiers, a group of patients who will meet
with LEO Pharma researchers during a series of workshops. The patients
will become an integrated part of LEO Pharma's innovation process and
focus on investigating needs, testing new care concepts and exploring
new solutions. The first task will be to consider patient needs in
relation to new formulations, devices and packaging.
The Psoriasis Frontiers group will focus both on conventional
pharmaceutical product innovation and on individualised care solutions
such as patient engagement concepts, access models, diagnostic tools
and digital technologies. Psoriasis Frontiers will act as a sounding
board, working only with concepts and not with marketed products.
Specific research findings will be subject to confidentiality; however,
partners are committed to publishing non-competitive findings to the
"National Psoriasis Foundation recognises the need for patient insight
into research and treatment development. This collaboration will allow
people living with the disease to meet face-to-face with scientists
creating the cutting-edge therapies they may use in their everyday
life," says Kathleen Gallant, chair of the National Psoriasis
Foundation Outreach Committee and member of its Board of Trustees.
"Who better to discuss product innovation and patient care than people
affected by the disease? Hopefully this 'patient-focused' research
concept becomes a trend that creates new opportunities."
About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions
to patients in more than 100 countries globally, the company supports
people in managing their skin conditions.
Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted
decades of research and development to delivering products and
solutions to people suffering from skin diseases.
LEO Pharma is headquartered in Denmark and employs around 5,000 people
For more information, visit http://www.leo-pharma.com.
About the National Psoriasis Foundation
The National Psoriasis Foundation is the world's largest non-profit
organisation serving people with psoriasis and psoriatic arthritis.
Our mission is to find a cure for psoriasis and psoriatic arthritis and
to eliminate their devastating effects through research, advocacy and
For more information, call the National Psoriasis Foundation,
headquartered in Portland, Ore., at +1-800-723-9166, or visit http://www.psoriasis.org. Follow the National Psoriasis Foundation on Facebook ( http://www.facebook.com/national.psoriasis.foundation) and Twitter ( http://www.twitter.com/npf).
SOURCE: LEO Pharma A/S
For further information:
Eva Juul Langlands, Corporate Communications Manager, Corporate Communications, Direct: +45-7226-2059, Mobile: +45-4188-3094, E-mail: email@example.com ; Noe Baker, Public Relations Manager, National Psoriasis Foundation, Direct: +1-503-546 8413, E-mail: firstname.lastname@example.org